MIKHAIL BLAGOSKLONNY’S STRIFE FOR A CANCER FREE TOMORROW.

Rapamycin, also known as Sirolimus was first discovered in 1972 form a sample of bacterium found in the Easter Islands and was initially used as an anti-fungal agent. But after a while, it was discovered that the wonder drug had immunosuppressive and antiproliferative properties that were unmatched. This led to its use in the treatment of different conditions.Some of the ailments treated or managed by the drug include; Immunosuppressant properties, treating patients with Hemolytic- Urenal Syndrome, treatment of Tuberous Sclerosis Complex (TSC), treatment of facial angiofibromas, treatment of Alzheimer’s disease (research ongoing), treatment of muscular dystrophy, systemic lupus erythematosus (SLE), coronary stent coating, treatment of lymphangioleiomyomatosis, treatment of cancer and increase longevity of a person.

One of the greatest advocates of this wonder drug is Mikhail Blagosklonny. Blagosklonny is a known Professor of Oncology at the Rosewell Park Cancer Institute in Buffalo, New York and also an authority in the field of aging research and is well known for advocating the use of Rapamycin for the purpose of increasing lifespan. He has done extensive research on this matter and has even done experiments on mice which showed that use of Rapamycin on aging rats has resulted in the increased ability of the mice to deal with tuberculosis. Although there is no conclusive data to show that the drug can increase longevity in a person, Blagosklonny has a firm belief that this drug can delay our deaths.

Blagosklonny has focused intensely in the field of cancer and aging simply because he wants to understand the correlation between cancer and age and the reason why cancer is more prevalent in older individuals above a certain age.Blagosklonny has a goal of figuring out a way of treating cancer in a manner that is not only efficient but also less excruciating and cheap to the numerous cancer patients across the world and do away with the narrative that cancer treatment is only for the rich in society. He wants to do away with the fear and hopelessness that accompanies the disease. Blagosklonny who continues to research cancer will still be useful in the field of oncology. He also hopes that his findings will inspire many people in the future to pick up from where he left off, and he believes that treatment of cancer in the future will be easy and cost-effective treatment.